Genomic Health

Uro Pipeline: FDA accepts priority review application for RCC treatmentAgents for bladder cancer, prostate cancer, and stress urinary incontinence are also included in this round-up of pipeline developments.
Biomarkers predict metastasis, biochemical recurrenceClinicians may soon be able to improve the risk stratification of men with prostate cancer with the help of a genomic classifier or a biopsy-based reverse transcription polymerase chain reaction assay, according to the results of two studies presented at the Genitourinary Cancers Symposium in Orlando, FL.
Markers redefining prostate cancer careIn this interview, Daniel W. Lin, MD, discusses the practical use of currently available molecular and genomic tests, cost and reimbursement considerations, the role of MRI, and what the future holds for biomarkers.
Data support PCa markers, but more study neededA leader in urologic oncology discusses four currently available molecular tests in this report from Urology Times SUO internship program member Brandon Manley, MD.
Test significantly impacts prostate Ca Tx recommendationsA new study assesses how a biopsy-based gene test impacts prostate cancer treatment recommendations in three high-volume practices.
January 2015 Product Preview: FDA committee recommends approval of complicated UTI agentDrugs and devices in the pipeline from Actavis, Genomic Health, Lipella Pharmaceuticals, Polaris Group, Innocrin Pharmaceuticals, OncoGenex Pharmaceuticals, Heat Biologics, Repros Therapeutics, and Sophiris Bio.
Prostate Ca assays show economic, clinical benefitsThe Prolaris prostate cancer test could save the health care system $6 billion over 10 years, according to data from one of several new studies examining the economic and clinical benefits of newer biomarker-based prostate cancer assays.
New biomarkers address key aspects of prostate Ca managementNew biomarkers for prostate cancer are showing great promise for addressing the limitations of existing diagnostic and prognostic tools, according to opinion leaders who spoke on this topic at the Large Urology Group Practice Association annual meeting in Chicago.
Genomic prostate score shown to predict BCRA prostate cancer diagnostic test may have benefits beyond predicting tumor aggressiveness, a study presented at the European Society for Medical Oncology Congress showed.
Low-risk PCa: Patients can make an informed decision
Low-risk PCa: Patients can make an informed decisionIn this interview, Ian Thompson, MD, answers questions about the downside of diagnosing low-risk prostate cancer, the burdens of active surveillance and how to minimize them, and how his own approach to screening and biopsy have changed.